Sign In
Buy SEER
Seer Earnings Calls
| Release date | May 13, 2026 |
| EPS estimate | -$0.295 |
| EPS actual | -$0.300 |
| EPS Surprise | -1.69% |
| Revenue estimate | 3.6M |
| Revenue actual | 2.793M |
| Revenue Surprise | -22.42% |
| Release date | Feb 26, 2026 |
| EPS estimate | -$0.320 |
| EPS actual | -$0.290 |
| EPS Surprise | 9.38% |
| Revenue estimate | 4.6M |
| Revenue actual | 4.201M |
| Revenue Surprise | -8.67% |
| Release date | Nov 06, 2025 |
| EPS estimate | -$0.320 |
| EPS actual | -$0.320 |
| Revenue estimate | 4.6M |
| Revenue actual | 4.121M |
| Revenue Surprise | -10.41% |
| Release date | Aug 06, 2025 |
| EPS estimate | -$0.390 |
| EPS actual | -$0.330 |
| EPS Surprise | 15.38% |
| Revenue estimate | 3.75M |
| Revenue actual | 4.051M |
| Revenue Surprise | 8.03% |
Last 4 Quarters for Seer
Below you can see how SEER performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $2.06 |
| EPS estimate | -$0.390 |
| EPS actual | -$0.330 |
| EPS surprise | 15.38% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $2.12 |
| Aug 01, 2025 | $2.13 |
| Aug 04, 2025 | $2.13 |
| Aug 05, 2025 | $2.12 |
| Aug 06, 2025 | $2.06 |
| Aug 07, 2025 | $2.01 |
| Aug 08, 2025 | $2.30 |
| Aug 11, 2025 | $2.21 |
| Aug 12, 2025 | $2.20 |
| 4 days before | -2.83% |
| 4 days after | 6.80% |
| On release day | -2.43% |
| Change in period | 3.77% |
| Release date | Nov 06, 2025 |
| Price on release | $2.16 |
| EPS estimate | -$0.320 |
| EPS actual | -$0.320 |
| Date | Price |
|---|---|
| Oct 31, 2025 | $2.21 |
| Nov 03, 2025 | $2.27 |
| Nov 04, 2025 | $2.19 |
| Nov 05, 2025 | $2.17 |
| Nov 06, 2025 | $2.16 |
| Nov 07, 2025 | $2.09 |
| Nov 10, 2025 | $2.09 |
| Nov 11, 2025 | $2.07 |
| Nov 12, 2025 | $2.08 |
| 4 days before | -2.26% |
| 4 days after | -3.70% |
| On release day | -3.24% |
| Change in period | -5.88% |
| Release date | Feb 26, 2026 |
| Price on release | $2.08 |
| EPS estimate | -$0.320 |
| EPS actual | -$0.290 |
| EPS surprise | 9.38% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $1.98 |
| Feb 23, 2026 | $2.06 |
| Feb 24, 2026 | $2.09 |
| Feb 25, 2026 | $2.09 |
| Feb 26, 2026 | $2.08 |
| Feb 27, 2026 | $1.72 |
| Mar 02, 2026 | $1.73 |
| Mar 03, 2026 | $1.80 |
| Mar 04, 2026 | $1.85 |
| 4 days before | 5.05% |
| 4 days after | -11.06% |
| On release day | -17.31% |
| Change in period | -6.57% |
| Release date | May 13, 2026 |
| Price on release | $1.77 |
| EPS estimate | -$0.295 |
| EPS actual | -$0.300 |
| EPS surprise | -1.69% |
| Date | Price |
|---|---|
| May 07, 2026 | $1.88 |
| May 08, 2026 | $1.87 |
| May 11, 2026 | $1.83 |
| May 12, 2026 | $1.82 |
| May 13, 2026 | $1.77 |
| May 14, 2026 | $1.75 |
| May 15, 2026 | $1.72 |
| May 18, 2026 | $1.69 |
| May 19, 2026 | $1.68 |
| 4 days before | -5.85% |
| 4 days after | -5.08% |
| On release day | -1.13% |
| Change in period | -10.64% |
Seer Earnings Call Transcript Summary of Q1 2026
Seer reported Q1 2026 revenue of $2.8M (down from $4.2M YoY) and a net loss of $16.8M, while reducing operating expenses to $18.2M. Management emphasized progress on scientific validation (84 peer-reviewed publications), expanding population-scale biobank partnerships (including the PRECISE‑SG100K collaboration), product and software innovation (SP200/Proteograph One assay, Raviant DIA search engine, and a next‑generation detector with a data showcase expected later in 2026), and a strengthened commercial leadership team with the hire of a new Chief Commercial Officer. The company is defending its IP (PTAB decision upheld many claims and a new infringement suit filed) and evolving its Seer Insight grant to accelerate biopharma adoption. Gross margin was 35% (impacted by lower absorption of fixed costs); management expects long‑term gross margins of 70–75% at scale. Seer repurchased shares under a buyback program (13.2M Class A shares repurchased to date) and ended the quarter with ~$219.5M in cash and investments, which management says is sufficient to reach cash‑flow breakeven. The company reaffirmed full‑year 2026 revenue guidance of $16M–$18M, expecting instrument utilization and consumable pull‑through to build through the year with revenue weighted to the back half.
